Steroid Injections in India: Uses, Risks & Stocking Guide
A clinical reference on intra-articular steroid injections for Indian prescribers: evidence, real risk profile, CDSCO/NPPA status and pharmacy stocking.
This covers what the evidence actually supports, the documented risks, how the drug class sits under Indian regulation, and why a hospital pharmacy's ability to stock and dispense it reliably matters operationally. It is not a guide to how much or how often to inject any individual patient.
What is an intra-articular steroid injection actually for?
An intra-articular corticosteroid injection delivers a concentrated anti-inflammatory dose directly into a joint space, most often the knee, to reduce synovitis and effusion during an acute painful flare of osteoarthritis or an inflammatory arthropathy. The mechanism is local, not systemic, which is the entire rationale for injecting rather than dosing orally.
The 2021 EULAR recommendation describes intra-articular long-acting glucocorticoid as indicated specifically for acute exacerbation of knee pain, especially where effusion is present, rather than as a routine or repeat maintenance therapy. That distinction, acute flare versus ongoing management, is where a lot of real-world prescribing drifts from the guideline.
Does the evidence actually support it long-term?
A systematic review and meta-analysis on corticosteroid injection effect in knee osteoarthritis found genuine short-term pain benefit but no evidence of effect on pain persisting beyond three to six months. The American Academy of Orthopaedic Surgeons' own clinical practice guideline stops short of a conclusive recommendation for or against use, which tells a prescriber the evidence base is real but limited, not absent.
That gap between short-term relief and long-term benefit is exactly why repeat dosing schedules deserve more scrutiny than a single flare-management injection does.
What does the evidence say about joint damage risk?
A case-control study found intra-articular corticosteroid knee injection was associated with a measurable reduction in meniscal thickness, with no corresponding benefit to cartilage volume, which raises a real structural question about repeated use in the same joint over time. This finding sits alongside a national cohort study from England that tracked rates of subsequent knee replacement and post-operative outcomes in patients who had received intra-articular corticosteroid injections before surgery.
A separate peer-reviewed review aimed specifically at orthopaedic providers flags that corticosteroid injection given close to a planned knee replacement raises infection risk at the surgical site, which is why most orthopaedic protocols now build in a defined injection-free window before elective arthroplasty. None of this makes the injection unsafe for its intended acute use; it means the timing relative to any planned surgery is a genuine clinical variable, not a scheduling afterthought.
How is this drug class regulated and priced in India?
Corticosteroids including prednisolone, methylprednisolone and triamcinolone formulations fall under CDSCO's regulatory oversight as the National Regulatory Authority under the Drugs and Cosmetics Act, 1940, and several formulations, including prednisolone and its salts, esters and derivatives, are listed as scheduled medicines by the National Pharmaceutical Pricing Authority. That scheduled status means ceiling prices are fixed and revised annually rather than left to open-market pricing.
A hospital pharmacy sourcing a steroid injection India stockist offers should verify the current NPPA-listed ceiling price for the specific formulation and strength before assuming a quoted rate is current, since scheduled-formulation prices change with each annual Wholesale Price Index revision. Dosage form, strength and pack size all affect which NPPA entry applies, and a mismatch between the SKU stocked and the SKU priced is a common sourcing error.
Why does hospital stocking reliability matter for an acute-use injection like this?
An intra-articular steroid injection is typically an unplanned, same-visit clinical decision made when a patient presents with an acutely painful, effusive joint, not a prescription filled days later. If the hospital's own pharmacy doesn't have the specific formulation and strength in stock at that moment, the patient either leaves without treatment or the prescription walks to an outside chemist entirely.
That single stockout doesn't just delay one injection. It breaks the visit-to-treatment loop the orthopaedic department depends on, and once a patient has been sent outside for one prescription, follow-up physiotherapy referrals, imaging and repeat visits often fragment across providers too. Our guide on prescription leakage and hospital revenue loss covers how a single unplanned stockout like this compounds into lost continuity across an entire treatment course, not just one missed sale.
What should an orthopaedic or hospital pharmacy stock, and how does a managed model help?
A hospital pharmacy serving an active orthopaedic or physiotherapy department needs reliable stock of the two or three corticosteroid formulations its own surgeons actually use, in the strengths they actually prescribe, rather than a broad speculative range. Matching stock to real prescribing pattern, not catalogue breadth, is the practical fix for the acute-use stockout problem described above.
Our managed hospital pharmacy services guide covers how a managed or in-house pharmacy model builds stocking around a department's actual prescribing data rather than generic assumptions, which is exactly the discipline an acute-use, unplanned-demand drug like a steroid injection India orthopaedic unit needs. Our pharmacy inventory management guide covers the expiry and reorder-point discipline that keeps a low-volume, high-value injectable like this from becoming dead stock between flare-ups.
Sources
- 1The Magnitude and Duration of the Effect of Intra-articular Corticosteroid Injections on Pain Severity in Knee Osteoarthritis: A Systematic Review and Meta-Analysis — PubMed, National Institutes of Health
- 2Intra-articular Corticosteroid Injections for Symptomatic Knee Osteoarthritis: What the Orthopaedic Provider Needs to Know — PubMed, National Institutes of Health
- 3Effect of intra-articular corticosteroid injections for knee osteoarthritis on the rates of subsequent knee replacement and post-operative outcomes — National Institutes of Health, National Library of Medicine
- 4Intra-articular corticosteroid knee injection induces a reduction in meniscal thickness with no treatment effect on cartilage volume — National Institutes of Health, National Library of Medicine
- 5Methyl Prednisolone — scheduled formulation pricing — National Pharmaceutical Pricing Authority, Government of India
- 6Central Drugs Standard Control Organisation — Drugs and Cosmetics Act 1940 and Rules 1945
*Written by Dr. Anurag Sharma, MBBS, MS (Orthopaedics) — Consultant Orthopaedic Surgeon and Assistant Professor at S.M.S. Medical College and Hospital, Jaipur. Last updated 23 July 2026.*
*This article is a clinical reference for prescribers and hospital administrators. It is informational only, is not a substitute for professional medical advice, and does not recommend any dose, frequency or treatment for any individual patient. Consult a qualified physician for patient-specific decisions.*
FAQ
Frequently asked questions
Systematic review evidence shows genuine short-term relief but no proven benefit on pain beyond roughly three to six months, which is why guidelines position it as flare management rather than a long-term therapy.
Case-control evidence has found measurable meniscal thickness reduction associated with intra-articular corticosteroid injection, with no offsetting benefit to cartilage volume, which supports treating repeat injections in the same joint as a decision with real structural trade-offs.
Peer-reviewed orthopaedic literature associates corticosteroid injection given close to a planned knee replacement with increased infection risk at the surgical site, which is why many protocols build in a defined injection-free interval before elective arthroplasty.
Prednisolone and several of its derivative formulations are listed as scheduled medicines under NPPA's Drug Price Control Order, meaning ceiling prices are fixed and revised annually rather than set purely by the market.
No. An intra-articular injection delivers the drug locally into the joint space for a local anti-inflammatory effect, while an oral course has systemic exposure and a different risk profile entirely; the two are not interchangeable treatment decisions.
Dr. Ananya DeshpandeMBBS, DM (Endocrinology)
Consultant Endocrinologist
Dr. Ananya Deshpande is a consultant endocrinologist writing on diabetes and insulin therapy, thyroid disorders, GLP-1 agonists, and metabolic conditions.